![Emily Bates PhD](https://profiles-cardiff.imgix.net/attachments/7548?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Emily Bates
(hi/ei)
PhD
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Emily Bates
Elusen Tiwmor yr Ymennydd Arweinwyr y Dyfodol Cymrawd Ôl-ddoethurol
Trosolwyg
🔬 Rwy'n gymrawd ymchwil yn labordy VITAL Prifysgol Caerdydd, lle cwblheais fy PhD yn 2022, gan ganolbwyntio ar therapïau adenofeirysol wedi'u haddasu ar gyfer glioblastoma. Yn dilyn fy PhD, cefais fy ariannu gan Ymchwil Canser Cymru a wnaeth fy ngalluogi i archwilio cymwysiadau therapïau adenofeirysol mewn canser yr ymennydd. Rwy'n falch iawn o fod wedi derbyn Cymrodoriaeth Arweinwyr y Dyfodol Elusen Tiwmor yr Ymennydd, yn 2024, sy'n canolbwyntio ar ddatblygu therapïau adenofeirysol newydd ar gyfer cleifion â'r math mwyaf cyffredin o ganser yr ymennydd oedolion, glioblastoma 🧠
Cyhoeddiad
2023
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
2022
- Bates, E. 2022. Developing Species D adenovirus vectors for cancer applications. PhD Thesis, Cardiff University.
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
2021
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
2020
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
Articles
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
Thesis
- Bates, E. 2022. Developing Species D adenovirus vectors for cancer applications. PhD Thesis, Cardiff University.
Bywgraffiad
Mae Dr. Emily Bates yn Gymrawd Arweinwyr y Dyfodol Elusen Tiwmor yr Ymennydd ym Mhrifysgol Caerdydd, sy'n canolbwyntio ar ddatblygu therapïau adenofeirysol newydd ar gyfer glioblastoma. Cwblhaodd ei PhD yn 2022, gan ymchwilio i fectorau adenofirws oncolytig ar gyfer cymwysiadau canser. Mae gan Dr. Bates wyth cyhoeddiad a adolygir gan gymheiriaid (pedwar awdur cyntaf) ac mae wedi'i enwi ar ddau gais am batent. Mae hi wedi derbyn Rhagoriaeth PGR mewn Arloesi, Gwobr Poster Peter Tomasec, a Gwobr Effaith Proffesiynol Gyrfa Gynnar ELRIG.
Enillodd Dr. Bates arbenigedd mewn virotherapi oncolytig yn ystod ei gradd meistr yn MedImmune, tra'n astudio ym Mhrifysgol Lerpwl. Mae cyfranogiad yn y Rhaglen Innovate UK, ICURe Explore, yn adlewyrchu ei hymrwymiad i gyfieithu ymchwil academaidd i driniaethau cleifion. Mae Dr. Bates wedi cyflwyno ei gwaith mewn cynadleddau allweddol ac wedi adeiladu cydweithrediadau gan ddatblygu rhwydwaith ymchwil cryf yn lleol, yng Nghaerdydd, yn ogystal ag yn rhyngwladol. Mae Dr. Bates hefyd yn cymryd rhan mewn digwyddiadau ymgysylltu â'r cyhoedd i hyrwyddo ymchwil canser ledled Cymru.
Contact Details
Adeilad Geneteg Canser, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Themâu ymchwil
Arbenigeddau
- Therapi canser
- Firoleg